SCHEMBL4151394

SCHEMBL4151394

CC(C)CC(C(=O)NC1N=C(c2ccccc2F)c2ccccc2N(CCC2CC2)C1=O)C1(C(N)=O)CC=CC1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NOTCH1 P46531 2/20 0.45
RBPJ Q06330 2/20 0.45
CCKBR P32239 16/20 0.43
CCKAR P32238 14/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13904805 1.00 NOTCH1 (0.45) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL4160293 0.90 CCKBR (0.45) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL13904804 0.90 CCKBR (0.45) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL4147285 0.86 NOTCH1 (0.44) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL13904798 0.86 NOTCH1 (0.44) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL13904802 0.86 NOTCH1 (0.44) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL13904840 0.80 CCKBR (0.51) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL4152395 0.80 CCKBR (0.51) NOTCH1RBPJCCKBRCCKARPSEN1
SCHEMBL13904669 0.79 NOTCH1 (0.65) NOTCH1RBPJCCKBRPSEN1PSEN2
SCHEMBL4159022 0.79 NOTCH1 (0.65) NOTCH1RBPJCCKBRPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US claimed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US claimed
US-20030119815-A1 Lactams substituted by cyclic succinates as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-06-26 US claimed
US-6509333-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-21 US claimed
US-20020137737-A1 Lactams substituted by cyclic succinates as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-26 US claimed
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-05 US disclosed
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US disclosed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US disclosed
US-7354914-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-04-08 US disclosed
US-20050261274-A1 Lactams substituted by cyclic succinates as inhibitors of Abeta protein production OLSON RICHARD E 2005-11-24 US disclosed
US-6958329-B2 Lactams substituted by cyclic succinates as inhibitors of A-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US disclosed
US-20030119815-A1 Lactams substituted by cyclic succinates as inhibitors of A-beta protein production OLSON RICHARD E (US) 2003-06-26 US disclosed
US-6509333-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-21 US disclosed
US-20020137737-A1 Lactams substituted by cyclic succinates as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137737-A1 Lactams substituted by cyclic succinates as inhibitors of a beta protein production APP, BACE1, APH1A NOTCH1 323/4885RBPJ 3065/4885CCKBR 2920/4885
US-20050261274-A1 Lactams substituted by cyclic succinates as inhibitors of Abeta protein production BACE1, APP, APH1A NOTCH1 166/4885RBPJ 3066/4885CCKBR 2683/4885
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BACE1, APP, APH1A NOTCH1 166/4885RBPJ 3066/4885CCKBR 2683/4885
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION APH1A, APH1B, APP NOTCH1 488/4885RBPJ 3018/4885CCKBR 2885/4885
US-20030119815-A1 Lactams substituted by cyclic succinates as inhibitors of A-beta protein production APH1A, APH1B, APP NOTCH1 301/4885RBPJ 2966/4885CCKBR 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.